Study

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. – Cost Effective Supplements

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

Quick navigation


http://www.ncbi.nlm.nih.gov/pubmed/29241357


Conclusion of this study

These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.


Supplements analyzed in this study

CBD

Health conditions analyzed in this study

Schizophrenia


Slightly Positive
CBD


Functions related to this study

Mental health


Slightly Positive
CBD


Body systems related to this study


Nervous System
Scroll to top